A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Abali, Huseyin; Yalcin, Suayib; Onal, Cem; Dane, Faysal; Oksuzoglu, Berna; Ozdemir, Nuriye; Mertsoylu, Huseyin; Artac, Mehmet; Camci, Celaletdin; Karabulut, Bulent; Basal, Fatma Bugdayci; Budakoglu, Burcin; Sendur, Mehmet Ali Nahit; Goktas, Burce; Ozdener, Fatih; Baygul, Arzu

doi:10.1200/JCO.2018.36.4\_suppl.26

A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Tarih

2018

Yazarlar

DOI No

10.1200/JCO.2018.36.4\_suppl.26

Diğer Tanımlayıcı No

WOS:000436174100026

Yayınevi

LIPPINCOTT WILLIAMS \& WILKINS

Özet

Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San Francisco, CA, JAN 18-20, 2018

URI

https://openaccess.acibadem.edu.tr/handle/11443/8317

Koleksiyonlar

WOS

Tam öğe sayfası

A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Tarih

Yazarlar

Süreli Yayın başlığı

Süreli Yayın ISSN

Cilt Başlığı

ISSN

DOI No

Diğer Tanımlayıcı No

Cilt

Sayı

Yayınevi

Özet

Açıklama

Anahtar kelimeler

Alıntı

URI

Koleksiyonlar

Endorsement

Review

Supplemented By

Referenced By